Skip to content

Inspection Record

Octapharma AB — FDA 483 Findings

US FDAInspected 2023-09-19Published 2026-10-26 3 findingsDeviation, CAPA, and investigationProcess validationEquipment and facility

Inspectors Alan L Truong · Ze Peng · Olga Simakova and 1 moreThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

Deviations from written production and process control procedures are not recorded and justified.

2Process validation

Written procedures are not established and followed that describe the in-process controls to be conducted on appropriate samples of in-process materials of each batch.

3Equipment and facility

Equipment and(b) (4) are not maintained at appropriate intervals to prevent that would alter the safety, identity, strength, quality or purity of the drug product.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Octapharma AB company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.